Amarin raises funding for heart drug, partnership worries pull down shares
(Reuters) – Biopharmaceutical company Amarin Corp Plc said it raised $100 million in non-equity financing that will help it form a sales force to launch its heart drug Vascepa, but disappointed investors hoping for a sale or partnership. Amarin shares fell 22 percent in extended trade, after closing at $11. 95 on the Nasdaq on Thursday. “(Strategic) discussions are still quite active but at some point we’ve got to move forward,” CEO Joseph Zakrzewski said on a conference call with analysts. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply